Our prototype assay’s expert development resulted in an assay with wide dynamic range, high precision and reproducible results, laying the foundation for the successful 22C3 PD-L1 companion diagnostic assay widely utilized today to select patients eligible for treatment with the anti-PD-1 immunotherapy pembrolizumab.
The programmed death receptor-1 (PD-1) pathway is one of the major immune-checkpoints that engages with tumor cells to avoid T-cell–mediated immune surveillance. The PD-1 receptor-1 ligand (PD-L1), which is often expressed by tumor cells, binds with PD-1 on T cells and delivers an inhibitor signal to down-regulate T cell proliferation and activation – enabling tumor expansion and growth.
Given its role in tumor progression, the PD-1 pathway is a common target for immunotherapies. The first clinical trial of a PD-L1-blocking drug began in 2006 in patients with a variety of tumors including melanoma, kidney, and lung. Today, six PD-1/L1 checkpoint inhibitor immunotherapies have been approved by the U.S. Food and Drug Administration for 14 different types of cancer, and PD-1/L1 inhibitors are being evaluated in more than 2,250 clinical trials.
© 2019 Discovery Life Sciences. All Rights Reserved.
